Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck Cancer

Bicara Therapeutics announced updated interim data from a Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab for first-lin...
Home/KnloSights/Clinical Trial Updates/Bicara Therapeutics Announces Positive Interim Data for Ficerafusp Alfa in Head and Neck Cancer